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Peptide hormones of the glucagon-like peptide (GLP) family play an increasing clinical role,
such as GLP-1 in diabetes therapy. Moreover, GLP receptors are overexpressed in vari-
ous human tumor types and therefore represent molecular targets for important clinical
applications. In particular, virtually all benign insulinomas highly overexpress GLP-1 recep-
tors (GLP-1R).Targeting GLP-1R with the stable GLP-1 analogs 111In-DOTA/DPTA-exendin-4
offers a new approach to successfully localize these small tumors. This non-invasive tech-
nique has the potential to replace the invasive localization of insulinomas by selective arterial
stimulation and venous sampling. Malignant insulinomas, in contrast to their benign coun-
terparts, express GLP-1R in only one-third of the cases, while they more often express the
somatostatin type 2 receptors. Importantly, one of the two receptors appears to be always
expressed in malignant insulinomas. The GLP-1R overexpression in selected cancers is
worth to be kept in mind with regard to the increasing use of GLP-1 analogs for diabetes
therapy. While the functional role of GLP-1R in neoplasia is not known yet, it may be safe
to monitor patients undergoing GLP-1 therapy carefully.
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INTRODUCTION
G protein-coupled peptide hormone receptors play an increasing
role as tumor targets in cancermedicine (Reubi, 2003). The under-
lying molecular basis is primarily an overexpression of a speciﬁc
peptide receptor on tumor cells, irrespective of receptor func-
tions. This overexpression allows a receptor-targeted scintigraphic
imaging and radiotherapy of tumors with adequate radiolabeled
peptide analogs (Reubi, 2003). Historically, the somatostatin
receptors were the ﬁrst receptors identiﬁed for these purposes
(Reubi, 2003). They are expressed in high incidence and at high
levels in gastroenteropancreatic neuroendocrine tumors (Reubi,
2003). Somatostatin receptor scintigraphy using the somatostatin
analog octreotide (OctreoScan) represents nowadays a stan-
dard imaging procedure for patients with gut neuroendocrine
tumors, while PET/CT with 68Ga-labeled somatostatin analogs
turns out to be even superior toOctreoScan (Gabriel et al., 2007).
Furthermore, results from clinical studies performing somato-
statin receptor-mediated radionuclide therapy are encouraging
(Kwekkeboom et al., 2008; Imhof et al., 2011).
The clinical success of somatostatin receptor targeting of gut
neuroendocrine tumors has stimulated the search for other pep-
tide receptors suitable for similar applications. A promising
candidate is the glucagon-like peptide 1 (GLP-1) receptor (GLP-
1R). This receptor has been cloned almost 20 years ago (Thorens
et al., 1993). It is a member of the class 2 G protein-coupled
receptor family (Gros et al., 1993; Nauck, 2009). Only a single
GLP-1R has been identiﬁed so far, which is structurally identi-
cal in all tissues (Thorens et al., 1993). Receptor activation upon
agonist binding stimulates adenylate cyclase and phospholipase C,
with subsequent activation of protein kinase A and C, respectively
(Thorens et al., 1993).
Physiologically, the GLP-1R is expressed mainly in the ali-
mentary tract, particularly in the pancreatic islet cells (Wei and
Mojsov, 1995) where it mediates the actions of GLP-1 released
from the small intestines in response to food intake. GLP-1 is con-
sidered to be one of themost important glucose-dependent insulin
secretagogues (Nauck, 2009). Speciﬁcally, it stimulates glucose-
dependent insulin synthesis and secretion, inhibits glucagon
secretion, decreases β-cell apoptosis and increases differentiation
of β-cell precursor cells in the pancreas as well as inhibits gas-
tric emptying and appetite at the hypothalamic level (Nauck et al.,
2009). Exploiting GLP-1 pathways therefore represents an ideal
therapeutic approach for patients with type 2 diabetes, as this
interferes with the main pathophysiological mechanisms of the
disease (Nauck et al., 2009). Indeed, synthetic GLP-1 analogs are
FDA- and EMEA-approved for the treatment of type 2 diabetes
(Nauck et al., 2009).
The GLP-1R is of clinical interest not only due to its physiologic
expression and functions in pancreatic islet cells and its potential
in diabetes therapy, but also because of its possible role in cancer.
Indeed, 10 years ago, the GLP-1R was found to be expressed in
insulin-producing islet cell tumors, i.e., insulinomas (Reubi and
Waser, 2003). This discovery lead to an extensive evaluation of the
potential of the GLP-1R for targeted tumor imaging and therapy
analogous to somatostatin receptor targeting of gut neuroen-
docrine tumors. This evaluation included the characterization of
human tumors and normal tissues for their GLP-1R expression,
since an important prerequisite for a successful peptide receptor
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targeting of tumors is a high receptor expression in tumors, but
a low receptor expression in normal background tissues. Fur-
ther activities included the development of adequate radiolabeled
GLP-1 analogs, testing of such analogs in in vivo animal models
and application of selected suitable candidate analogs to tumor
patients in preliminary clinical studies. This review summarizes
the knowledge on the in vitro and in vivo basis of GLP-1 receptor
targeting of tumors accumulated in the last decade.
GLP-1R IN TUMORS
TheGLP-1R expression has been systematically assessed in a broad
spectrum of original human tumor tissues using in vitro recep-
tor autoradiography (Reubi and Waser, 2003; Korner et al., 2007;
Waser et al., 2011). The GLP-1R was thus identiﬁed in speciﬁc
endocrine, embryonal, and brain tumors, but virtually not in
carcinomas (Table 1). The most striking GLP-1R expression was
found in insulinoma. This is an endocrine tumor of the pan-
creatic islet cells with mostly benign biological behavior, but
characterized clinically by severe symptoms of hyperinsulinism
due to insulin secretion. Benign insulinomas expressed GLP-1Rs
in very high incidence (>90%) and extremely high density (Reubi
Table 1 | GLP-1R expressing human tumors: receptor incidences and
densities.
Tumor type GLP-1R incidence GLP-1R density*
Endocrine tumors
Benign insulinomas 25/27 (93%) 8,133
Malignant insulinomas 4/11 (36%) 8,508†
Gastrinomas 10/10 (100%) 2,461
Glucagonomas 2/4 (50%) 910
VIPomas 1/4 (25%) 3,028
Ileal carcinoids 8/27 (30%) 1,027
Bronchial carcinoid tumors 11/29 (38%) 2,456
Pheochromocytomas 12/20 (60%) 3,970
Paragangliomas 5/18 (28%) 1,353
Medullary thyroid carcinomas 5/18 (28%) 1,326
Embryonal tumors
Medulloblastomas 3/12 (25%) 1,246
Nephroblastomas 2/9 (22%) 421
Neuroblastomas 3/16 (19%) 932
Brain tumors
Meningiomas 7/20 (35%) 989
Astrocytomas 4/16 (25%) 1,069
Glioblastomas 2/21 (9%) 790
Ependymomas 1/6 (16%) 1,075
Carcinomas
Ovarian adenocarcinomas 2/12 (16%) 688
Prostate adenocarcinomas 1/20 (5%) 1,283
*dpm/mg tissue.
†Mean value of two tumors tested with in vitro GLP-1R autoradiography.
and Waser, 2003; Table 1; Figure 1). In fact, no other peptide
receptor has been found to exhibit such high expression levels
in this tumor type (Reubi and Waser, 2003). On the contrary,
malignant, metastasizing insulinomas expressed GLP-1Rs signiﬁ-
cantly less frequently. High GLP-1R levels were found in only 36%
malignant insulinomas (Wild et al., 2011). In insulinoma cells, the
GLP-1R may represent a mediator of insulin secretion: in a model
of GLP-1R transfected insulinoma cells, glucose-mediated insulin
release was increased compared to control cells, in parallel with
an increase of the intracellular second messenger of the GLP-1R
(cAMP; Montrose-Raﬁzadeh et al., 1997).
Also several other functioning endocrine tumors of the pan-
creas expressed GLP-1Rs, in particular gastrinomas, however
in lower amounts compared with insulinomas (Table 1; Reubi
and Waser, 2003). Moreover, GLP-1Rs were discovered in a
number of extrapancreatic endocrine tumors, including ileal
carcinoids, pheochromocytomas, paragangliomas, bronchial car-
cinoid tumors, and medullary thyroid carcinomas, while they
were not identiﬁed in pituitary adenomas or adrenal cortical
tumors (Korner et al., 2007). Pheochromocytomas are of partic-
ular clinical interest due to their high GLP-1R expression levels
(Table 1). Furthermore, medullary thyroid carcinomas are note-
worthy because of important species differences in their GLP-1R
expression. In rats, virtually all medullary thyroid carcinomas
expressed GLP-1Rs in high amounts (Waser et al., 2011), while
in humans only 28% expressed GLP-1R at low density levels
(Table 1).
Lower GLP-1R expression levels were found in embryonal
tumors, including medulloblastoma, nephroblastoma, and neu-
roblastoma (Table 1). They showed GLP-1Rs in low density in
15–25% of the tumors (Korner et al., 2007). Similarly, tumors
of the nervous system such as meningiomas and astrocytomas
demonstrated an incidence of GLP-1Rs between 25 and 35%,
whereas glioblastomas and ependymomas expressed GLP-1Rs in
9–16% (Table 1; Korner et al., 2007). Schwannomas were devoid
of GLP-1Rs (Korner et al., 2007).
Conversely, carcinomas exhibited a very low or no GLP-1R
expression. Only ovarian and prostate carcinomas rarely showed
GLP-1R at low levels, while breast, colorectal, gastric, pancreatic,
hepatocellular, and cholangiocellular as well as lung carcinomas
(non-small and small cell carcinomas) were negative for GLP-1R
(Korner et al., 2007). Likewise, non-Hodgkin lymphomas did not
express GLP-1R (Korner et al., 2007).
Among all GLP-1R expressing tumor types, insulinomas are
at present of highest clinical interest for an in vivo targeting
in patients, based on several considerations. First, insulinomas
exhibit particularly high GLP-1R expression levels with respect
to both incidence and density. Second, benign insulinomas, in
contrast to most other gastroenteropancreatic neuroendocrine
tumors, show relatively low expression levels of somatostatin
receptors. Consequently, OctreoScan is not a reliable tool to
detect these tumors (Plockinger et al., 2004). Third, the exact
intraoperative localization of insulinomas is critical in order to
minimize the surgical intervention (Rostambeigi and Thompson,
2009). This is, however, difﬁcult due to the small size of benign
insulinomas (usually 10–20 mm). Conventional radiological pro-
cedures (endosonography, MR-, and CT-imaging) are not always
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FIGURE 1 | Hormone and receptor determinations in vitro in a
benign insulinoma. (A) Immunohistochemistry for insulin showing
strongly labeled tumor cells. Bar = 0.01 mm. (B–D) In vitro GLP-1R
autoradiography on consecutive insulinoma tissue sections.
(B) Hematoxylin & eosin (H&E) staining showing the tumor tissue.
Bar = 1 mm. (C) Autoradiogram showing total binding of 125I-GLP-1(7-36)
amide. The entire tumor is strongly positive. (D) Autoradiogram showing
non-speciﬁc binding of 125I-GLP-1(7-36) amide in the presence of 100 nM
cold GLP1(7-36) amide. Reprinted from Christ et al. (2010), with permission
from Elsevier.
successful in localizing insulinomas (Chatziioannou et al., 2001).
Moreover, [18F]DOPA PET shows at present controversial results,
with sensitivities ranging between 17 and 90% (Kauhanen et al.,
2007; Tessonnier et al., 2010). Although selective arterial stimula-
tion and venous sampling is a reliable intraoperative tool to detect
insulinomas in experienced institutions (Wiesli et al., 2004), it is
an invasive procedure with the associated risks. Moreover, this
procedure identiﬁes only the region of the pancreas – depending
on the vasculature – where the insulinoma should be located and
not the tumor itself (Wiesli et al., 2004).
GLP-1R IN NON-NEOPLASTIC TISSUES
TheGLP-1R expressionwas similarly characterized in human nor-
mal tissues. It has been found in the pancreatic islets and acini,
stomach, duodenal Brunner’s gland, small and large intestinal
myenteric plexus, lung andkidney vasculature, breast parenchyma,
heart, brainstem, hypothalamus, neurohypophysis, and meninges
(Wei and Mojsov, 1995; Korner et al., 2007). In vitro receptor
autoradiography revealed that GLP-1R levels were highest in the
neurohypophysis, followed by Brunner’s glands, meninges, and
pancreatic islets (Korner et al., 2007). Of practical importance,
with the exception of Brunner’s glands, the different tissues in the
pancreatic area (i.e., pancreas islets and acini, intestines, and kid-
ney) exhibit far lower GLP-1R density levels than insulinomas.
This results in a high tumor-to-background ratio in GLP-1R
density levels for insulinomas, which is an important prerequisite
for a GLP-1R-targeted scintigraphic imaging of insulinomas.
Prominent species differences in the physiological GLP-1R
expression between humans and rodents are noteworthy. Indeed,
autoradiography experiments indicate that GLP-1R density lev-
els are considerably higher in the lungs of rats and mice than of
humans (Korner et al., 2007). This has to be considered when
interpreting results of in vivo testing of GLP-1R targeting in
rodent models. Likewise, the GLP-1R expression in the thyroid
gland is substantial in rodents, but virtually absent in humans
(Korner et al., 2007). In rodent thyroids, GLP-1Rs are located in
themedullaryC-cells. Of interest, treatmentwithGLP-1 analogs in
rats is known to occasionally lead to thyroid C-cell hyperplasia and
medullary thyroid carcinoma, whereas in humans there is so far
no evidence of such complications. It can be speculated whether
the species differences in the GLP-1R density expression in the
precursor cells of these tumors, the medullary C-cells, contribute
to these controversial ﬁndings (Waser et al., 2011).
RADIOLABELED GLP-1 ANALOGS
In general, radioactively labeled peptide analogs represent phar-
maceuticals with favorable characteristics. Due to their small
size, they show fast diffusion and rapid blood clearance and lack
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immunogenicity. Moreover, radiopeptides exhibit only rare side
effects (Reubi, 2003). In addition, radiolabeling is easily feasi-
ble, preferably after attaching a chelator to the peptide (Reubi
and Maecke, 2008). However, since peptides are physiologically
degraded within minutes in the human blood by potent pepti-
dases such as dipeptidyl-peptidase-4 (DPP-4; Baggio and Drucker,
2007), stable peptide analogs have to be used instead in clinical
applications. As for GLP-1, a naturally occurring stable analog
exists, namely exendin-4, which is a component of the Gila mon-
ster venom. It shares 53% homology with GLP-1 and similarly
binds toGLP-1Rs, but is resistant toDPP-4 cleavage (Nauck,2009).
Exendin-4 is, therefore, a good candidate for the development of
radiolabeled GLP-1R ligands.
The ﬁrst radiopeptides tested for in vivo GLP-1R targeting
were 125I-labeled GLP-1 and the GLP-1 analog exendin-3 (Got-
thardt et al., 2002). However, the low peptide stability of GLP-1
and the low efﬁciency of radio-iodination of exendin-3 limited
their clinical use. Further testing resulted in the development of
111In-labeled exendin-4 (Wild et al., 2006): exendin-4 was coupled
via the Lys side chain to a chelator (DOTA, tetraazacyclodo-
decane tetraacetic acid or DTPA, diethylenetriaminepentaacetic
acid) using a spacer (Ahx, aminohexanoic acid) and then labeled
with 111In. This radiopeptide was subsequently extensively tested
in vitro and in vivo in insulinoma models and applied to insuli-
noma patients (see below). Lately, several studies have been pub-
lished that describe GLP-1R ligands suitable for PET/CT imaging,
such as 68Ga-, 64Cu-, or 18F-labeled exendin-4, or for SPECT/CT
imaging like 99mTc-labeled exendin-4 (Brom et al., 2010; Wild
et al., 2010; Wu et al., 2011; Kiesewetter et al., 2012). These novel
radiopeptides have not yet been tested in insulinoma patients.
GLP-1R TARGETING IN ANIMAL MODELS
Initially, GLP-1R targeting was performed in the rat insulinoma
cell line RINm5F and in a rat insulinoma animal model (NEDH
rats) using 125I-labeled GLP-1 and exendin-3 (Gotthardt et al.,
2002). Speciﬁc uptake was detected in the cell and animal mod-
els. This provided the proof of principle for GLP-1R targeting of
insulinoma (Gotthardt et al., 2002).
Follow-up experiments were carried out in the Rip1tag2
mouse model with 111In-DTPA-exendin-4. These transgenic mice
develop tumors of the pancreatic β-cells in a reproducible multi-
stage fashion (Hanahan, 1985) and, therefore, represent an ideal
model to study GLP-1R targeting in vivo and in vitro. Using GLP-
1R multipinhole SPECT/MRI and SPECT/CT, in vivo GLP-1R
imaging was performed in these animals following administration
of 111In-DTPA-exendin-4 (Wild et al., 2006). In parallel, GLP-1R
autoradiography of the tumors was carried out in vitro. Finally,
biodistribution and pharmacokinetics as well as internalization
and cellular retention of 111In-DTPA-exendin-4 were measured
in vitro (Wild et al., 2006).
This preclinical study showed the following main ﬁndings:
First, the GLP-1R density in the tumors was extremely high,
resulting in a remarkably high uptake of 111In-DTPA-exendin-
4 (287 ± 62% IA/g tissue) already 4 h after injection. Second,
excellent visualization of tumors as small as 1 mm by pin-
hole SPECT/MRI and SPECT/CT was demonstrated. Third, the
tumor-to-background ratio was very high (between 13.6 and 299),
substantiating the high potential of this radiopeptide to speciﬁ-
cally localize GLP-1R positive lesions within the pancreas. Lastly,
in vitro studies in the cells derived from the tumor model demon-
strated a speciﬁc internalization of 111In-DTPA-exendin-4, and
biochemical investigations conﬁrmed the high metabolic stability
of the radiopeptide in the tumor cells as well as in the serum.
The same Rip1tag2 mouse model also provided preliminary
data on GLP-1R-targeted therapy of insulinoma. Mice were
injected with different doses of 111In-DTPA-exendin-4 (1.1, 5.6,
and 28 MBq) and sacriﬁced 7 days after injection. Most impres-
sively, a single injection lead to a reduction in tumor volume
of up to 94% in a dose-dependent manner without signiﬁcant
acute organ toxicity. Histological examination revealed that the
decrease in tumor mass was mainly due to an increase in tumor
cell apoptosis and decreased proliferation (Wicki et al., 2007).
GLP-1R TARGETING IN HUMANS
The ﬁrst patient who underwent GLP-1R scintigraphy suf-
fered from severe endogenous hyperinsulinemic hypoglycemia
with non-convulsive seizures. MRI, CT scan, and endosonog-
raphy did not detect any suspicious lesion. However, GLP-1R
scintigraphy revealed an increased extrapancreatic uptake in the
mesentery supplied by the anterior mesentery artery. Selective
arterial stimulation and venous sampling correctly indicated the
vascular territory, but since this patient had an ectopic insuli-
noma, the results of the invasive investigation without GLP-1R
imagingwouldhavebeenmisleading for the surgical strategy (Wild
et al., 2008).
In a proof of principle study, 111In-DOTA-exendin-4 was
prospectively administered to a total of six patients (Christ et al.,
2009). All of them presented with neuroglycopenic symptoms
lasting for 4–26 months. Biochemical evaluation during a fast-
ing test revealed endogenous hyperinsulinemic hypoglycemia in
all patients.
Conventional imaging (CTorMRI) reliably detected the insuli-
noma in only two patients, whereas endosonography identiﬁed a
possible lesion in four patients, in keeping with data in the liter-
ature (McAuley et al., 2005). In three patients, selective arterial
stimulation and venous sampling was performed, with accu-
rate localization in all (Christ et al., 2009). Remarkably, GLP1-R
scintigraphy correctly detected the insulinoma in all six con-
secutive patients (Figure 2; Christ et al., 2009). Four patients
underwent an enucleation of the insulinoma. In two patients,
a Whipple procedure had to be performed due to the localiza-
tion of the insulinoma. In all patients, a benign insulinoma was
conﬁrmed by histology. In vitro autoradiography studies showed
GLP-1R densities in the range as previously described (between
2,600 to>10,000 dpm/mg tissue; Reubi and Waser, 2003), but low
levels of somatostatin receptor type 1 in 2 patients only (Christ
et al., 2009). Importantly, within a time frame of 2–14 days after
injection of 111In-DOTA-exendin-4, intraoperative utilization of
a gamma probe was highly beneﬁcial for the in situ localization of
the insulinoma in all patients, resulting in a successful enucleation
where possible (Christ et al., 2009).
Fortunately, background uptake over the whole body was low
with the exceptions of the kidneys, which were strongly labeled
due to renal excretion of the radioligand (Figure 2). In two
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FIGURE 2 | 111In-DOTA-exendin-4 whole-body planar images (A–C)
and 111In-DOTA-exendin-4 SPECT/CT images (D,E) from the same
patient.Whole-body scans were carried out 20 min (A), 4 h (B), and 3 days
(C), and SPECT/CT scans were performed 4 h (D) and 3 days (E) after
injection of 97 MBq 111In-DOTA-exendin-4. Four hours after injection, there
was already a focal 111In-DOTA-exendin-4 uptake visible in the head of the
pancreas (arrow) on whole-body (B) and SPECT/CT (D) scans. The
tumor-to-pancreas-uptake ratio was 1.9 at 4 h after injection (D) and 3.2 at 3
days after injection of the radioligand. The longest residence times of
111In-DOTA-exendin-4 were observed in the tumor (arrow) and kidneys
(C). Reprinted from Christ et al. (2009), with permission fromThe Endocrine
Society.
patients demarcation between tumors (maximal diameter of 9–
11 mm) and kidneys was only possible after late scans, indicating
an improved tumor-to-kidney ratio with time, in keeping with
the fact that the effective half-life of 111In-DOTA-exendin-4 was
longer in the tumor (38–64 h) than in the kidneys (31.2–31.8 h;
Figure 2; Christ et al., 2009). This suggests that patients with neg-
ative early scans should have additional imaging 3–7 days after the
injection.
In humans, 111In-DOTA-exendin-4 was initially administered,
but later replaced by 111In-DTPA-exendin-4 due to the four times
higher speciﬁc activity of the latter (Wild et al., 2009). A higher
speciﬁc activity permits to reduce the amount of peptide (exendin-
4), thereby decreasing the occurrence of possible side effects. In
addition, radiolabeling of DTPA-exendin-4 can be performed at
room temperature, whereas labeling of DOTA-exendin-4 has to be
accomplished at high temperature (95◦C; Wild et al., 2006).
By now, data of a prospective, multicenter trial includ-
ing 30 patients that underwent GLP-1R scanning are available.
The inclusion criteria were proven endogenous hyperinsulinemic
hypoglycemia and none or maximally one lesion on conventional
imaging. Conventional imaging (CT, MRI) and endosonography
– where available – was performed locally using a standard pro-
tocol. 111In-DTPA-exendin-4 was administered intravenously at a
dose of 90–130 MBq over 2 min. Whole-body planar images and
SPECT/CT of the abdomen were performed at 4, 24 and in some
patients between 72 and 96 up to 168 h post-injection, the most
important time point being the scan 24 h after injection. Dia-
gnosis was conﬁrmed by histology after surgical removal (Christ
et al., 2012).
Conventional imaging (MRI, CT, endosonography) was pos-
itive in 17 patients. 111In-DTPA/DOTA-exendin-4 SPECT/CT
detected 23 true positive benign insulinomas and ﬁve additional
positive lesions (one malignant insulinoma; two islet cell hyper-
plasias; two uncharacterized lesions). True negative tests were
detected in two patients (one malignant insulinoma; one islet
cell hyperplasia). Malignant insulinomas were diagnosed based
on the histological ﬁnding of a positive lymph node, not detected
on conventional imaging preoperatively. There was no false nega-
tive result. Sensitivity was 100% and the positive predictive value
was 82% (Christ et al., 2012). These ﬁndings are encouraging
and suggest that in vivo GLP-1R imaging deﬁnes a new non-
invasive diagnostic approach to successfully localize small benign
insulinomas.
About 90% of insulinomas are benign and only 10% of
patients present with malignant disease usually characterized by
liver metastasis (Plockinger et al., 2004). Anecdotal evidence sug-
gests that malignant insulinomas exhibit more often somatostatin
receptors type 2 than benign ones and can, therefore, be visualized
by OctreoScan (Plockinger et al., 2004). A more extensive study
with data from10patientswithmalignant insulinoma showed that
somatostatin receptors type 2 were expressed in seven patients,
whereas GLP-1R were present in four patients, and both receptors
in only one patient (Wild et al., 2011). Importantly, one of the
two imaging methods appears always to be positive in a malig-
nant type of insulinoma (Wild et al., 2011). The consequences of
the respective receptor expression in an insulinoma with regard to
biological behavior (malignant or benign course) remains to be
established.
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SIDE EFFECTS AND LIMITATIONS
In humans, the injection of 111In-DOTA-exendin-4 and 111In-
DPTA-exendin-4 was well tolerated. Due to the small amount
of exendin-4, the decrease in plasma glucose concentrations was
only 1.4 ± 0.7 mmol/L after 40 min (Christ et al., 2009). By regu-
larly monitoring glucose levels, no severe hypoglycemic episode
occurred. One patient experienced a short episode of vomit-
ing only with 111In-DOTA-exendin-4. Otherwise, no further side
effects were observed (Christ et al., 2009).
In two patients, there was focal 111In-DOTA-exendin-4 uptake
in the proximal duodenum. This may be related to the presence
of Brunnner’s gland of the duodenum which, as previously men-
tioned, are known to contain GLP-1Rs in a signiﬁcant density
(Korner et al., 2007). Brunner’s glands may become hyperplastic
(Levine et al., 1995), as observed in particular in patients with
chronic pancreatitis (Stolte et al., 1981). Such hyperplastic glands
may possibly be detected by GLP-1R imaging.
A differential diagnosis of endogenous hyperinsulinemic
hypoglycemia includes nesidioblastosis, also known as “non-
insulinoma pancreatogenous hypoglycemia syndrome” in a clini-
cal setting (Thompson et al., 2000). Histopathologically, this entity
is deﬁned as a diffuse hyperplasia of β-cells occurring usually
in children (Yakovac et al., 1971). Recent evidence suggests that
this pathology can also be demonstrated in adults, in particular
after bypass surgery for morbid obesity (Service et al., 2005). In
the previously mentioned series of patients (Christ et al., 2012),
islet cell hyperplasia was diagnosed in three patients, two were
positive on GLP-1R imaging and one was negative. Based on
these preliminary data GLP-1R imaging does not appear to be
an appropriate tool to diagnose or exclude islet cell hyperplasia.
These ﬁndings are further supported by the recent evidence that
the in vitro density of GLP-1R in pancreatic tissues of patients
with nesidioblastosis after bypass surgery for morbid obesity is
much lower than in benign insulinomas (Reubi et al., 2010).
Recently, 18F-DOPA-PET has successfully been used to detect
nesidioblastosis and benign insulinoma (Kauhanen et al., 2007).
Although 18F-DOPA-PET may be helpful to diagnose nesidioblas-
tosis, in benign insulinomas the tumor-to-background ratios are
higher for 111In-DOTA-exendin-4 SPECT than for 18F-DOPA-
PET (3.3 vs. 1.4), suggesting an increased sensitivity of targeting
GLP-1Rs (Kauhanen et al., 2007; Christ et al., 2009) in benign
insulinomas.
SUMMARY AND CONCLUSION
Because of the massive GLP-1R overexpression in selected gas-
trointestinal tumors, GLP-1 and GLP-1R play an increasing role
in endocrine gastrointestinal tumor management. Targeting GLP-
1R with 111In-DOTA-exendin-4 or 111In-DPTA-exendin-4 offers
a new approach that permits the successful localization of small
benign insulinomas pre- and intraoperatively. Since virtually all
benign insulinomas express GLP-1Rs and the preliminary clinical
data are very encouraging, it is likely that this approach will affect
the algorithm of pre- and intraoperative localization of suspected
insulinoma.
In contrast to benign insulinomas, where the exact localization
of the tumor is the main goal, the clinical challenge in malignant,
metastasizing insulinomas is to deﬁne the extension of the dis-
ease and – if possible – offer a targeted therapy (peptide receptor
radionuclide therapy, PRRT). Contrary to benign insulinomas,
malignant insulinomas more often express sst2 receptors than
GLP-1R. Importantly, one of the two receptors seems to be always
expressed.
With regard to the increasing and successful use of GLP-1
analogs for diabetes therapy, it is worth keeping in mind that
selected cancers can overexpress GLP-1R. While the functional
role of these receptors in these tumors is not known yet, it may be
safe to monitor patients with such tumors carefully during their
GLP-1-analog-based diabetes therapy.
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